Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine efficacy study for uncomplicated falciparum malaria in Mauritania
ACTRN12614001107617Phase 4Not yet recruiting
- Sponsor
- Ministry of Health
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether and lumefantrine in Malaria, sponsored by Ministry of Health. Primary endpoint: WHO-classified treatment outcome over 28 days. Planned start Nov 2014; status: not yet recruiting.
02
Drugs
artemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on ACTRN12614001107617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001107617.